Search FHTX
Foghorn Therapeutics Inc.
Nasdaq · CIK 1822462
Last close2.02
Daily change-0.90 (-30.82%)
10 Years gain-88.85%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
FHTX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
68.2Momentum
100.0Acceleration
100.0Confidence
78.0Annual Revenue6
Quarterly Revenue20
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth20.5 / 25
Quality16.4 / 25
Capital Efficiency16.3 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 195.6746 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 12.3801%.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM36.39%OK
Revenue CAGR 3Y17.14%OK
Gross Margin100%OK
Operating Margin-199.65%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y138.83%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y12.38%OK
SBC / Revenue29.67%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $30.91M | $30.91M | -$86.39M | -$86.10M | -$86.15M | 100% | -279.49% | -278.72% | n/a | 62.98M |
| 2025 FY Dec 31, 2024 | $22.60M | $22.60M | -$102.68M | -$100.41M | -$101.31M | 100% | -454.31% | -448.24% | n/a | 54.9M |
| 2024 FY Dec 31, 2023 | $34.16M | $34.16M | -$107.91M | -$118.11M | -$119.33M | 100% | -315.93% | -349.38% | n/a | 41.97M |
| 2023 FY Dec 31, 2022 | $19.23M | $19.23M | -$117.14M | $193.61M | $192.40M | 100% | -609.2% | 1,000.63% | n/a | 41.59M |
| 2022 FY Dec 31, 2021 | $1.32M | $1.32M | -$100.73M | -$50.25M | -$53.56M | 100% | -7,637.15% | -4,060.88% | -231.4% | 37.17M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $35.05M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-053819, 0001628280-25-049238 |
| Revenue Growth TTM | 36.39% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-053819, 0001628280-25-049238 |
| Revenue CAGR 3Y | 17.14% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-016814 |
| Revenue CAGR 5Y | 135.14% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-016814 |
| Gross Profit CAGR 3Y | 17.14% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-016814 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-053819, 0001628280-25-049238 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001628280-26-053819, 0001628280-25-049238 |
| Operating Margin | -199.65% | Operating Income / Revenue | OK | 0001628280-26-053819, 0001628280-25-049238 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-053819 |
| Current Ratio | 3.36x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 29.67% | SBC / Revenue | OK | 0001628280-26-053819, 0001628280-25-049238 |
| Revenue per Diluted Share | $0.50 | Revenue / Diluted Shares | OK | 0001628280-26-053819, 0001628280-25-049238 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | 0001628280-26-053819, 0001628280-25-049238 |